Astrazeneca (AZN) Short term Debt (2009 - 2025)

Astrazeneca's Short term Debt history runs 16 years deep, the most recent figure standing at $3.1 billion for Q4 2025.

• In Q4 2025, Short term Debt rose 32.82% year-over-year to $3.1 billion; the TTM figure through Dec 2025 stood at $3.1 billion (up 32.82% YoY), while the FY2025 annual figure was $3.1 billion, up 32.82% from the prior year.
• Short term Debt was $3.1 billion for Q4 2025 at Astrazeneca, up from $2.3 billion in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $5.3 billion in Q4 2022 to a low of $143.0 million in Q1 2021.
• Historically, Short term Debt has averaged $2.9 billion across 5 years, with a median of $2.7 billion in 2024.
• The sharpest annual moves came in 2022 and 2024: Short term Debt surged 220.12% in 2022, then plunged 54.44% in 2024.
• A 5-year view of Short term Debt shows it stood at $1.7 billion in 2021, then soared by 220.12% to $5.3 billion in 2022, then retreated by 3.48% to $5.1 billion in 2023, then plunged by 54.44% to $2.3 billion in 2024, then jumped by 32.82% to $3.1 billion in 2025.
• The last three Short term Debt figures came in at $3.1 billion (Q4 2025), $2.3 billion (Q4 2024), and $5.1 billion (Q4 2023), per Business Quant data.